Solasia Pharma KK

Solasia Pharma KK has a market price of 32.0 JPY and a market cap of 8.74 billion JPY, with a price-to-book ratio of 4.99 and a price-to-tangible-book ratio of 4.99. The company has a debt-to-equity ratio of 0.05 and a current ratio of 6.06, indicating strong liquidity. However, the company has negative operating and net income, with operating income of -861 million JPY and net income of -876 million JPY. The company's return on equity is -0.5 and return on assets is -0.4084, both significantly below the industry median for pharmaceuticals. The company's operating cash flow is -847 million JPY, and free cash flow is -839 million JPY, indicating a lack of positive cash generation. Solasia Pharma KK's revenue is concentrated in its core business of pharmaceuticals for malignant tumor treatment, with no disclosed geographic diversification. The company's main business area is the development and sale of pharmaceuticals for the treatment of malignant tumors, with a pipeline of products aimed at reducing adverse events and improving patient quality of life. The company's revenue for the latest period is 429 million JPY, with no capital expenditure recorded. Analysts have set a mean price target of 47.00 JPY, suggesting a potential upside of 46.88% from the current market price. However, the company's negative operating and net income, along with negative cash flows, indicate a challenging growth trajectory. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company has a low dilution potential, with shares outstanding basic and diluted at 273,005,222. The valuation adjustments applied in the custom valuations do not indicate significant dilution risk. Recent events include the company's continued focus on its pipeline of pharmaceuticals and medical devices, with no significant new filings or transcripts reported. The company's strategy involves in-licensing rights for pharmaceutical or medical device candidate substances, development of pharmaceutical candidates, and monetization of pharmaceutical candidates.